Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog – Page 4,990

The California PUC granted Waymo a permit to operate 24 hours/day in San Francisco taking select members of the public for rides with no safety driver in the vehicle. Waymo says it will begin this shortly. This comes on the heels of them expanding such service in Phoenix, as reported in my article on how the death of self-driving cars has been greatly exaggerated earlier this week.

This service will be with “trusted testers” rather than members of the broad public that can ride in Chandler and Phoenix, Arizona.

Waymo gets a permit to take the public and will start running with trusted testers. They also start in LA and show off their new robotaxi. Cruise also ups its game. Zoox got into an accident but it was in manual. Aurora reminds us they do more than trucks.

Read more | >

The patients wake up from anaesthesia with the cancer treated.

There’s a new robotic technology that finds lung cancer early and also has the ability to treat it at the same time, according to a report by CBS Philadelphia.

The American Lung Association’s annual report revealed that lung cancer survival rates are on the rise thanks partially to this new technology. The five-year survival rate is now estimated at 25%.

One example of this success is Kathleen McGinn, who found her cancer early and treated it with the new robotic procedure. “I’m very optimistic for my future,” McGinn told CBS.

“We’re up to 25% survival at five years, which is significantly up from the 17% survival in 2015. We attribute most of this to early detection, better treatments and systemic therapies for patients who have lung cancer that spread to other parts of the body,” said Dr. Bobby Mahajan with the American Lung Association said.

Patients who never smoked.

Continue reading “New ‘revolutionary’ robotic technology helps both treat and prevent lung cancer in one shot” | >

Originally published on Towards AI the World’s Leading AI and Technology News and Media Company. If you are building an AI-related product or service, we invite you to consider becoming an AI sponsor. At Towards AI, we help scale AI and technology startups. Let us help you unleash your technology to the masses.

Read more | >

A mechanism has been discovered that regulates cellular levels of tau, a protein whose aberrant accumulation is at the root of tauopathies, a class of devastating neurodegenerative diseases.

The finding was discovered in the laboratory of Michel Cayouette, director of cellular neurobiology research at the Montreal Clinical Research Institute (IRCM) and a medical professor at the University of Montreal.

The research, which was recently published in the journal Science Advances, demonstrates how the protein known as ‘numb’ regulates intracellular tau levels, making numb a potential therapeutic agent for tauopathies.

Read more | >

Back pain is a common condition with numerous causes, including poor posture, overexertion, constant stress at work or at home, lack of exercise, and poor posture. For a considerable number of patients, the symptoms are chronic, meaning they last a long period or reoccur repeatedly. However, port and exercise therapy, when done properly, can provide alleviation.

Physiotherapy, as well as strength and stability exercises, are common treatment options. But how can the treatment be as effective as possible? Which method reduces pain the most effectively? A recent meta-analysis published in the Journal of Pain by Goethe University Frankfurt revealed new insights.

The researchers began with data from 58 randomized controlled trials (RCTs) involving over 10,000 individuals suffering from chronic low back pain throughout the globe. The relevant data from the original manuscripts were first filtered out and then analyzed in groups. When analyzing this data, the researchers looked at whether and how conventional forms of therapy and individualized treatment varied in terms of outcome. “Individualized” refers to some kind of personal coaching where therapists precisely target the needs and potentials of each patient and collaborate with them to choose the course of their treatment.

Read more | >

To show how computer chips are improving a bit, my first computer, an Apple II+ based on the 6,502 chip, had 7 bytes of memory on the chip. Nvidia’s H100 chip has 85,986,377,728 bytes of memory on it!

The 6,502 was a very successful chip and is still made today, with over 6 billion units sold!

(My home PC has about 283,506,646,208 bytes of memory but that is contained in multiple chips.)

(typically pronounced “sixty-five-oh-two” or “six-five-oh-two”)[3] is an 8-bit microprocessor that was designed by a small team led by Chuck Peddle for MOS Technology. The design team had formerly worked at Motorola on the Motorola 6800 project; the 6,502 is essentially a simplified, less expensive and faster version of that design.

When it was introduced in 1975, the 6,502 was the least expensive microprocessor on the market by a considerable margin. It initially sold for less than one-sixth the cost of competing designs from larger companies, such as the 6,800 or Intel 8080. Its introduction caused rapid decreases in pricing across the entire processor market. Along with the Zilog Z80, it sparked a series of projects that resulted in the home computer revolution of the early 1980s.

Continue reading “MOS Technology 6502” | >

AI-generated art has arrived.

With a presentation making its debut this week at The Museum of Modern Art in New York City — perhaps the world’s premier institution devoted to modern and contemporary art — the AI technologies that have upended trillion-dollar industries worldwide over the past decade will get a formal introduction.

Created by pioneering artist Refik Anadol, the installation in the museum’s soaring Gund Lobby uses a sophisticated machine-learning model to interpret the publicly available visual and informational data of MoMA’s collection.

Read more | >

“There are no hard limits imposed by biology or by physics that says that we can’t live better longer,” Kristen Fortney, CEO of San Francisco-based BioAge Labs, told the outlet. Focused on discerning the markers of aging, BioAge Labs is using large amounts of biobank blood and tissue samples to do so.

The company has already found a drug target that slows aging-linked muscle loss in mice.

“There is a protein called apelin that circulates in the blood, and we saw that middle-aged people with higher levels of apelin in their blood were living longer, with better muscle function and better cognitive function as they age,” Fortney said, according to Express.

Read more | >